Circle Pharma Reports the First Patient Dosing with CID-078 Under P-I Study for Advanced Solid Tumors
Shots:
- Circle Pharma has dosed the first patient with CID-078 under the P-I clinical evaluation. Patients are enrolled at sites in Michigan, Utah, and Texas, with more locations to open soon
- The P-I study is a dose escalation and expansion trial that will assess the safety, preliminary anti-tumor activity & PK/PD of CID-078 for the treatment of patients (n=100) with advanced solid tumors. The preliminary outcomes are anticipated in 2025
- CID-078 (oral) is a macrocycle which possess dual cyclin A & B RxL inhibitory activity to target tumor cells causing cell cycle dysregulation. It showed tumor regression in xenograft models, leading its development to P-I
Ref: Circle Pharma | Image: Circle Pharma
Related News:- Circle Pharma Features Preclinical Results of CID-078 at the WCLC 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
